Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from At the heart of unmet need: TP53 myeloid neoplasms. Local targets link to admitted publications; unresolved targets remain external evidence.
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
10.1038/s41375-022-01613-1 · 2022 · External reference
International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data
10.1182/blood.2022015850 · 2022 · External reference
TP53-mutated acute myeloid leukemia: how can we improve outcomes?
10.1182/blood.2024024245 · 2025 · External reference
The tumor suppressor p53: from structures to drug discovery
10.1101/cshperspect.a000919 · 2010 · External reference
How to lose tumor suppression
10.1126/science.aay4319 · 2019 · External reference
Mutational landscape and significance across 12 major cancer types
10.1038/nature12634 · 2013 · External reference
What have we learned about TP53-mutated acute myeloid leukemia?
10.1038/s41408-024-01186-5 · 2024 · External reference
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
10.1126/science.aax3649 · 2019 · External reference
Characterization and clinical implications of p53 dysfunction in patients with myelodysplastic syndromes
10.1200/jco-24-02394 · 2025 · External reference
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
10.1182/blood.2020006158 · 2020 · External reference
Age-related clonal hematopoiesis associated with adverse outcomes
10.1056/nejmoa1408617 · 2014 · External reference
Prediction of risk for myeloid malignancy in clonal hematopoiesis
10.1056/evidoa2200310 · 2023 · External reference
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
10.1016/s1470-2045(16)30627-1 · 2017 · External reference
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
10.1016/s1470-2045(16)30626-x · 2017 · External reference
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
10.1038/s41591-020-1008-z · 2020 · External reference
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
10.1182/bloodadvances.2021006239 · 2022 · External reference
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts
10.1038/s41375-021-01486-w · 2022 · External reference
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion
10.1182/blood.2024023840 · 2024 · External reference
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
10.1038/leu.2016.263 · 2017 · External reference
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
10.1182/blood.2022016867 · 2022 · External reference
TP53 mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance
10.1002/ajh.27609 · 2025 · External reference
TP53 mutations and their impact on survival in patients with myeloproliferative neoplasms
2023 · External reference
Multihit TP53 mutations in myeloproliferative neoplasms and acute myeloid leukemia: comparative analysis of survival and risk factors in 142 informative cases
10.1002/ajh.27670 · 2025 · External reference
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status
10.1038/leu.2017.230 · 2018 · External reference
Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia
10.1038/s41408-024-01087-7 · 2024 · External reference
Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
10.1182/bloodadvances.2023010312 · 2023 · External reference
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
10.1182/bloodadvances.2024015238 · 2025 · External reference
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
10.1186/s13045-023-01480-y · 2023 · External reference
TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes
10.1056/nejmoa1605949 · 2016 · External reference
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
10.1182/bloodadvances.2020003508 · 2021 · External reference
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
10.1016/s2352-3026(18)30182-0 · 2019 · External reference
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
10.1182/bloodadvances.2020003120 · 2020 · External reference
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax
10.1002/cncr.33689 · 2021 · External reference
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study
10.1182/blood.2024027408 · 2025 · External reference
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · 2020 · External reference
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort
10.1182/blood.2024025834 · 2024 · External reference
A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes
10.1182/blood-2025-487 · 2025 · External reference
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
10.1182/blood-2017-06-788497 · 2017 · External reference
Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation
10.1056/nejmoa1611604 · 2017 · External reference
Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
10.1200/jco.23.00866 · 2023 · External reference
Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia
10.1002/cncr.34268 · 2022 · External reference
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
10.1182/blood-2016-12-754796 · 2017 · External reference
Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations
10.1182/bloodadvances.2024015335 · 2025 · External reference
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
10.1038/s41375-020-0997-4 · 2021 · External reference
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
10.1002/hem3.70164 · 2025 · External reference
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
10.1182/bloodadvances.2020002544 · 2020 · External reference
Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy
2025 · External reference
Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes
10.1200/jco.22.00181 · 2022 · External reference
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
10.1200/jco.2005.07.061 · 2005 · External reference
Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
10.1038/s41409-021-01515-3 · 2022 · External reference
The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease
10.1007/s00277-023-05276-5 · 2023 · External reference
Hypomethylating agent-based combination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia
10.3389/fonc.2021.810387 · 2022 · External reference
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
10.1182/blood.2024027506 · 2025 · External reference
Randomized phase II study to assess the role of nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (NCI9706 protocol; REMAIN Trial)
10.1182/blood-2022-157326 · 2022 · External reference
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
10.1182/bloodadvances.2021006138 · 2022 · External reference
Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study
10.1158/2159-8290.cd-18-0774 · 2019 · External reference
Combined blockade of CD47-sirpa interaction by 5F9 (magrolimab) and azacitidine/venetoclax therapy facilitates macrophage-mediated anti-leukemia efficacy in aml pre-clinical models
10.1182/blood-2021-147479 · 2021 · External reference
Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia
2018 · External reference
Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study
10.1200/jco.22.01794 · 2023 · External reference
Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results
10.1200/jco.22.02604 · 2023 · External reference
Azacitidine, venetoclax, and magrolimab in newly diagnosed and relapsed refractory acute myeloid leukemia: phase Ib/II study and correlative analysis
10.1158/1078-0432.ccr-25-0229 · 2025 · External reference
Trial in progress: a randomized, double-blind, placebo-controlled, multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (AK117–205)
2024 · External reference
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
10.1016/j.ccr.2009.03.003 · 2009 · External reference
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
10.1038/s41419-018-0463-7 · 2018 · External reference
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
10.3324/haematol.2020.259531 · 2022 · External reference
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies
10.1182/blood.2025028803 · 2025 · External reference
Phase 1 study of rezatapopt, a p53 reactivator, in TP53 Y220C-mutated tumors
10.1056/nejmoa2508820 · 2026 · External reference
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia
10.1182/blood.2025028935 · 2025 · External reference
The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells
10.1158/2159-8290.cd-19-0125 · 2019 · External reference
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers
10.1016/j.ccell.2024.04.004 · 2024 · External reference
Preliminary anti-leukemia activity from a phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
10.1182/blood-2025-768 · 2025 · External reference
Novel immunotherapies in the treatment of AML: is there hope?
10.1182/hematology.2023000455 · 2023 · External reference
Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with relapsed/refractory acute myeloid leukemia (R/R AML)
2025 · External reference
CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia
10.1182/blood.2025029532 · 2025 · External reference
